Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0086543 (
cataract
)
29,165
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We studied surgical experiences within a regional cohort of patients with
Duchenne muscular dystrophy
, managed at a single center. Records of all patients with confirmed
Duchenne muscular dystrophy
who were born after 1962 were reviewed from birth until they reached study endpoints: scoliosis surgery, Achilles tendon lengthening,
cataract
surgery, loss to follow-up, or final follow-up point in 2009. A survival analysis was used to account for the variable follow-up duration within this cohort. By the end of the study period, 28/80 (35.0%) of boys with
Duchenne muscular dystrophy
had undergone spinal surgery, 22/80 (27.5%) had experienced Achilles tendon lengthening, and 6/80 (7.5%) had had cataracts removed. Moreover, 56.8% of this cohort received steroid therapy (prednisone or deflazacort; 95% confidence interval, 43.3-68.8%). Boys who had received steroid therapy were significantly less likely to undergo spinal surgery (P = 0.001), but were subsequently more likely to require
cataract
surgery (P = 0.005). Achilles tendon lengthening did not seem related to medication exposure. The treatment of patients with
Duchenne muscular dystrophy
with steroids significantly modified their surgical experience.
...
PMID:Impact of steroids on surgical experiences of patients with duchenne muscular dystrophy. 2069 38
Deflazacort is the most commonly prescribed corticosteroid for the treatment of
Duchenne muscular dystrophy
in Canada. We review the long-term experience with deflazacort treatment at two centers in Canada; Montreal and Toronto. Deflazacort has benefitted both cohorts by prolonged ambulation, preserved cardiac and respiratory function, less scoliosis and improved survival. Common side effects in both cohorts include weight gain, decreased height and
cataract
formation. The Canadian experience supports the use of deflazacort in treating boys with
Duchenne muscular dystrophy
.
...
PMID:The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy. 2265 12